[
  {
    "sentence": "Transcription was higher in breast cancer than in any other cancer or paired healthy tissue (Figure 1a) [35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Breast cancer ACBD3 expression had a larger interquartile range, smaller minimum value, higher maximum value, and more numerous and distant outliers beyond the maximum range and were significantly higher than in matched healthy tissue (Figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Breast cancer had one of the highest levels of ACBD3 protein expression by the methodology used (11 out of 11 patient samples had medium levels of ACBD3 staining) (Figure 1c).2.2.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Breast cancers were found to have the highest proportion of ACBD3 gene amplifications, at 8.76%, relative to other cancers such as uterine and prostate (Figure 2), and mutation frequency was low across all the cancers examined.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In breast cancer, ACBD3 mutations occurred in 5 out of 1084 patients; these included E212Q, E226K, E348Q, and R523T mutation, as well as a E348Nfs*21 frame shift deletion (Figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The amplification rate of ACBD3 in breast cancer was less than expected based on the ACBD3 transcriptional upregulation observed with the GEPIA tool (Figure 1) and the commonality of chromosome 1q amplification in breast cancer [34].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In this study, tumor sample ACBD3 promoter methylation was not found to be significantly different from paired normal tissue methylation (* p = 0.86), and methylation was observed to be very low in both cases (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The transcriptomics function of the SPP was used to find regulators of ACBD3 expression that caused a fold change of two or more for all tissues (Figure 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In breast tissue specifically, the insulin receptor pathway related X10 ligand and the FOXA1 transcription factor were shown to increase ACBD3 transcription by two-fold or more (Figure 4b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "High tumor ACBD3 was also associated with less overall survival in HER2- tumors (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Red data points represent patients whose breast tumors had ACBD3 mRNA expression above the median level. (a–d) Relapse-free survival when ACBD3 is high or low for (a) breast cancer patient cohort overall, (b) HER2− breast cancer patients, (c) ER+ breast cancer patients, (d) ER−breast cancer patients. (e,f) Overall survival when tumor ACBD3 is high or low for (e) the breast cancer patient cohort overall, (f) ER+ breast cancer patients. (g–i) Overall distant metastasis-free survival when tumor ACBD3 was high or low for (g) the breast cancer patient cohort overall, (h) HER2− breast cancer patients, (i) ER+ breast cancer patients.Median relapse free survival (RFS) survival was 229 months when ACBD3 was expressed below the median and 173 months when ACBD3 expression was above the median (Figure 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "RFS was significantly lower in HER2− patients with ACBD3 expression above the median (43 months) compared to below the median (74 months) (Figure 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "RFS was not significantly different when triple negative breast cancer patients were divided by median ACBD3, but both ER+ and ER− groups had less RFS when tumor ACBD3 was expressed above the median (Figure 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The probability of overall survival (OS) was reduced in breast cancer patients with tumor ACBD3 expression above the median level (Figure 5e).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel e",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel e",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ER+ patients had less OS when ACBD3 expression was above the median (* p = < 0.05) (Figure 5f), but these changes were not as large as those seen in RFS differences (Figure 5c).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Distant metastasis-free survival (DMFS) was less likely when ACBD3 expression was high: the upper quartile DMFS was 138 months for the cohort as a whole when ACBD3 was expressed below the median level in breast tumor and 68 months when ACBD3 was expressed above the median (Figure 5f).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "HER2− patients were at greater risk of distant metastasis when ACBD3 was high in their tumors (Figure 5g).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel g",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel g",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ER+ patients were more likely to have distant metastasis if tumor ACBD3 was above the median level: upper quartile DMFS was 75 months when ACBD3 was high and 143 months when ACBD3 was low (Figure 5h).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel h",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel h",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ACBD3 expression was higher in patients who had pathological complete response to combination chemotherapy regimens (FAC: 5-fluorouracil, doxorubicin, cyclophosphamide; FEC: 5-fluorouracil, epirubicin, cyclophosphamide; CMF: cyclophosphamide, methotrexate, 5-fluorouracil), as well as to individual agents such as ixabepilone, taxane, and anthracycline (Figure 6a).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This observation is a strong contrast to data in Figure 5, where high ACBD3 expression had consistently negative patient outcomes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ACBD3 expression was not significantly different between those that had 5 years relapse-free survival and those that relapsed before 5 years following chemotherapy (Figure 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nBreast tumor ACBD3 expression in patients when divided by response or non-response to therapies. (a) ACBD3 expression in breast chemotherapy responders and non-responders; ACBD3 is 1.1 times higher in responders than in non-responders to chemotherapy overall in breast cancer (* p = 7.8 × 10−6). (b) ACBD3 expression in HER2− chemotherapy responders and non-responders; ACBD3 mRNA expression is 1.2 times higher in HER2− responders to chemotherapy (* p = 5.1 × 10−11). (c) ACBD3 expression in HER2+ responders and non-responders to any chemotherapy; ACBD3 is 1.2 times higher in HER2+ non-responders to chemotherapy (* p = 0.0029). (d) ACBD3 expression in responders and non-responders to trastuzumab; ACBD3 expression is 1.2 times higher in non-responders to trastuzumab (* p = 0.01). (e) ACBD3 expression in responders and non-responders to lapatinib; ACBD3 is 1.2 times higher in non-responders to lapatinib (* p = 0.011). (f) ACBD3 expression in HER2+ responders and non-responders to anthracycline; ACBD3 is 1.2 times higher in HER2+ non-responders to anthracycline (* p = 0.0023).HER2+ breast cancer patients who had complete pathological response to chemotherapy had lower ACBD3 RNA expression than those who did not respond (Figure 6c).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel c",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel c",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Patients who responded to trastuzumab and lapatinib anti-HER2 therapies specifically also had significantly lower ACBD3 expression than those who did not respond (Figure 6d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel d",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Anthracycline treatment also appeared to be more effective in patients with low ACBD3 expression (Figure 6f).2.7.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel f",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel f",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 represents typical ACBD3 staining of breast cancer tissue.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There were areas of higher staining at the ducts or lobules with surrounding tissue showing low or no staining for ACBD3 (Figure 7a).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "At 40× magnification, individual cells of both regular and irregular lobules could be seen; luminal epithelial cells that line of the lobules had strong staining for ACBD3, as do the myoepithelial basal layer of cells beneath (Figure 7b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel b",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel b",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "At 60× magnification, individual cells of the regular acini (Figure 7c) and irregular acini with invasive cells (Figure 7d) could be seen.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7e shows a core from an invasive ductal carcinoma, ACBD3 protein staining (brown) overall was low despite high coverage of haematoxylin nucleus staining (blue).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7f also shows an invasive ductal carcinoma and contained many more small ducts, and in this case, invasive cells in the ducts had higher staining of ACBD3 compared to the surrounding tissue.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel f",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7g shows a normal adjacent breast tissue core from a 41-year-old female with ducal ectasia.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel g",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7h shows a core of cancer adjacent tissue with benign adenosis (enlarged numerous lobules).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel h",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "ACBD3 Protein Expression in Malignant Breast Tissue and Metastatic Lymph Node Tissue\nThere was no statistical difference between ACBD3 protein expression between malignant breast tissue and metastatic breast cancer in lymph node (Figure 8a).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "ACBD3 protein levels were significantly higher in PR− breast cancers (mean = 3.296) compared to breast cancers with high expression of PR (PR 3+) (mean = 2.642) (* p = 0.022) (Figure 8b).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Although most normal-adjacent tissue cores detached during staining, three partial cores were scored and had a mean score of 2.70; whilst this small sample size could not reach any statistical conclusions, it was lower than the mean average for the breast cancer tissue cores overall (3.25), which is in keeping with the previous literature but contradictory to the results of Figure 8, where ACBD3 protein expression was higher in breast cancer cell lines than a normal-like breast cell control [22].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "ACBD3 Protein Expression Is Lower in Malignant Breast Tissue Compared to Cancer Adjacent and Normal Adjacent Breast Tissue\nContrary to previous reports [22], ACBD3 protein staining results for this array found ACBD3 protein staining to be statistically lower in malignant breast cancer tissue compared to adjacent tissue or normal adjacent tissue (Figure 8c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel c",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel c",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "ACBD3 Protein Expression in Malignant Breast Tissue of Multiple Subtype Receptor Status and Pathology\nArray BR1401 held no cases of breast cancer with PR 3+ receptor status, as such, the results from Figure 8b could not be corroborated in a larger sample size.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "HER2− breast cancer samples had significantly higher ACBD3 protein expression than HER2 1+ breast cancer samples (2.038, n = 49, versus 1.055, n = 4, respective mean averages, p = 0.0107) (Figure 8d).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Transcription was higher in breast cancer than in any other cancer or paired healthy tissue (Figure 1a) [35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Breast cancer ACBD3 expression had a larger interquartile range, smaller minimum value, higher maximum value, and more numerous and distant outliers beyond the maximum range and were significantly higher than in matched healthy tissue (Figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Breast cancer had one of the highest levels of ACBD3 protein expression by the methodology used (11 out of 11 patient samples had medium levels of ACBD3 staining) (Figure 1c).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Transcription was higher in breast cancer than in any other cancer or paired healthy tissue (Figure 1a) [35].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel a",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Breast cancer ACBD3 expression had a larger interquartile range, smaller minimum value, higher maximum value, and more numerous and distant outliers beyond the maximum range and were significantly higher than in matched healthy tissue (Figure 1b).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel b",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Breast cancer had one of the highest levels of ACBD3 protein expression by the methodology used (11 out of 11 patient samples had medium levels of ACBD3 staining) (Figure 1c).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Breast cancers were found to have the highest proportion of ACBD3 gene amplifications, at 8.76%, relative to other cancers such as uterine and prostate (Figure 2), and mutation frequency was low across all the cancers examined.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In breast cancer, ACBD3 mutations occurred in 5 out of 1084 patients; these included E212Q, E226K, E348Q, and R523T mutation, as well as a E348Nfs*21 frame shift deletion (Figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The amplification rate of ACBD3 in breast cancer was less than expected based on the ACBD3 transcriptional upregulation observed with the GEPIA tool (Figure 1) and the commonality of chromosome 1q amplification in breast cancer [34].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Breast cancers were found to have the highest proportion of ACBD3 gene amplifications, at 8.76%, relative to other cancers such as uterine and prostate (Figure 2), and mutation frequency was low across all the cancers examined.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In breast cancer, ACBD3 mutations occurred in 5 out of 1084 patients; these included E212Q, E226K, E348Q, and R523T mutation, as well as a E348Nfs*21 frame shift deletion (Figure 2c).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel c",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The amplification rate of ACBD3 in breast cancer was less than expected based on the ACBD3 transcriptional upregulation observed with the GEPIA tool (Figure 1) and the commonality of chromosome 1q amplification in breast cancer [34].",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In this study, tumor sample ACBD3 promoter methylation was not found to be significantly different from paired normal tissue methylation (* p = 0.86), and methylation was observed to be very low in both cases (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In this study, tumor sample ACBD3 promoter methylation was not found to be significantly different from paired normal tissue methylation (* p = 0.86), and methylation was observed to be very low in both cases (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The transcriptomics function of the SPP was used to find regulators of ACBD3 expression that caused a fold change of two or more for all tissues (Figure 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In breast tissue specifically, the insulin receptor pathway related X10 ligand and the FOXA1 transcription factor were shown to increase ACBD3 transcription by two-fold or more (Figure 4b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The transcriptomics function of the SPP was used to find regulators of ACBD3 expression that caused a fold change of two or more for all tissues (Figure 4a).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel a",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In breast tissue specifically, the insulin receptor pathway related X10 ligand and the FOXA1 transcription factor were shown to increase ACBD3 transcription by two-fold or more (Figure 4b).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel b",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "High tumor ACBD3 was also associated with less overall survival in HER2- tumors (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Red data points represent patients whose breast tumors had ACBD3 mRNA expression above the median level. (a–d) Relapse-free survival when ACBD3 is high or low for (a) breast cancer patient cohort overall, (b) HER2− breast cancer patients, (c) ER+ breast cancer patients, (d) ER−breast cancer patients. (e,f) Overall survival when tumor ACBD3 is high or low for (e) the breast cancer patient cohort overall, (f) ER+ breast cancer patients. (g–i) Overall distant metastasis-free survival when tumor ACBD3 was high or low for (g) the breast cancer patient cohort overall, (h) HER2− breast cancer patients, (i) ER+ breast cancer patients.Median relapse free survival (RFS) survival was 229 months when ACBD3 was expressed below the median and 173 months when ACBD3 expression was above the median (Figure 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "RFS was significantly lower in HER2− patients with ACBD3 expression above the median (43 months) compared to below the median (74 months) (Figure 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "RFS was not significantly different when triple negative breast cancer patients were divided by median ACBD3, but both ER+ and ER− groups had less RFS when tumor ACBD3 was expressed above the median (Figure 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The probability of overall survival (OS) was reduced in breast cancer patients with tumor ACBD3 expression above the median level (Figure 5e).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel e",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel e",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ER+ patients had less OS when ACBD3 expression was above the median (* p = < 0.05) (Figure 5f), but these changes were not as large as those seen in RFS differences (Figure 5c).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Distant metastasis-free survival (DMFS) was less likely when ACBD3 expression was high: the upper quartile DMFS was 138 months for the cohort as a whole when ACBD3 was expressed below the median level in breast tumor and 68 months when ACBD3 was expressed above the median (Figure 5f).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "HER2− patients were at greater risk of distant metastasis when ACBD3 was high in their tumors (Figure 5g).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel g",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel g",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ER+ patients were more likely to have distant metastasis if tumor ACBD3 was above the median level: upper quartile DMFS was 75 months when ACBD3 was high and 143 months when ACBD3 was low (Figure 5h).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel h",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel h",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "High tumor ACBD3 was also associated with less overall survival in HER2- tumors (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Median relapse free survival (RFS) survival was 229 months when ACBD3 was expressed below the median and 173 months when ACBD3 expression was above the median (Figure 5a).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel a",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "RFS was significantly lower in HER2− patients with ACBD3 expression above the median (43 months) compared to below the median (74 months) (Figure 5b).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel b",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "RFS was not significantly different when triple negative breast cancer patients were divided by median ACBD3, but both ER+ and ER− groups had less RFS when tumor ACBD3 was expressed above the median (Figure 5c,d).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "The probability of overall survival (OS) was reduced in breast cancer patients with tumor ACBD3 expression above the median level (Figure 5e).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel e",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel e",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ER+ patients had less OS when ACBD3 expression was above the median (* p = < 0.05) (Figure 5f), but these changes were not as large as those seen in RFS differences (Figure 5c).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Distant metastasis-free survival (DMFS) was less likely when ACBD3 expression was high: the upper quartile DMFS was 138 months for the cohort as a whole when ACBD3 was expressed below the median level in breast tumor and 68 months when ACBD3 was expressed above the median (Figure 5f).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel f",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "HER2− patients were at greater risk of distant metastasis when ACBD3 was high in their tumors (Figure 5g).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel g",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel g",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ER+ patients were more likely to have distant metastasis if tumor ACBD3 was above the median level: upper quartile DMFS was 75 months when ACBD3 was high and 143 months when ACBD3 was low (Figure 5h).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel h",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel h",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ACBD3 expression was higher in patients who had pathological complete response to combination chemotherapy regimens (FAC: 5-fluorouracil, doxorubicin, cyclophosphamide; FEC: 5-fluorouracil, epirubicin, cyclophosphamide; CMF: cyclophosphamide, methotrexate, 5-fluorouracil), as well as to individual agents such as ixabepilone, taxane, and anthracycline (Figure 6a).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This observation is a strong contrast to data in Figure 5, where high ACBD3 expression had consistently negative patient outcomes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ACBD3 expression was not significantly different between those that had 5 years relapse-free survival and those that relapsed before 5 years following chemotherapy (Figure 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nBreast tumor ACBD3 expression in patients when divided by response or non-response to therapies. (a) ACBD3 expression in breast chemotherapy responders and non-responders; ACBD3 is 1.1 times higher in responders than in non-responders to chemotherapy overall in breast cancer (* p = 7.8 × 10−6). (b) ACBD3 expression in HER2− chemotherapy responders and non-responders; ACBD3 mRNA expression is 1.2 times higher in HER2− responders to chemotherapy (* p = 5.1 × 10−11). (c) ACBD3 expression in HER2+ responders and non-responders to any chemotherapy; ACBD3 is 1.2 times higher in HER2+ non-responders to chemotherapy (* p = 0.0029). (d) ACBD3 expression in responders and non-responders to trastuzumab; ACBD3 expression is 1.2 times higher in non-responders to trastuzumab (* p = 0.01). (e) ACBD3 expression in responders and non-responders to lapatinib; ACBD3 is 1.2 times higher in non-responders to lapatinib (* p = 0.011). (f) ACBD3 expression in HER2+ responders and non-responders to anthracycline; ACBD3 is 1.2 times higher in HER2+ non-responders to anthracycline (* p = 0.0023).HER2+ breast cancer patients who had complete pathological response to chemotherapy had lower ACBD3 RNA expression than those who did not respond (Figure 6c).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel c",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel c",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Patients who responded to trastuzumab and lapatinib anti-HER2 therapies specifically also had significantly lower ACBD3 expression than those who did not respond (Figure 6d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel d",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Anthracycline treatment also appeared to be more effective in patients with low ACBD3 expression (Figure 6f).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel f",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel f",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "ACBD3 expression was higher in patients who had pathological complete response to combination chemotherapy regimens (FAC: 5-fluorouracil, doxorubicin, cyclophosphamide; FEC: 5-fluorouracil, epirubicin, cyclophosphamide; CMF: cyclophosphamide, methotrexate, 5-fluorouracil), as well as to individual agents such as ixabepilone, taxane, and anthracycline (Figure 6a).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This observation is a strong contrast to data in Figure 5, where high ACBD3 expression had consistently negative patient outcomes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "ACBD3 expression was not significantly different between those that had 5 years relapse-free survival and those that relapsed before 5 years following chemotherapy (Figure 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "HER2+ breast cancer patients who had complete pathological response to chemotherapy had lower ACBD3 RNA expression than those who did not respond (Figure 6c).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel c",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel c",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Patients who responded to trastuzumab and lapatinib anti-HER2 therapies specifically also had significantly lower ACBD3 expression than those who did not respond (Figure 6d,e).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel d",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Anthracycline treatment also appeared to be more effective in patients with low ACBD3 expression (Figure 6f).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel f",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel f",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Figure 7 represents typical ACBD3 staining of breast cancer tissue.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There were areas of higher staining at the ducts or lobules with surrounding tissue showing low or no staining for ACBD3 (Figure 7a).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "At 40× magnification, individual cells of both regular and irregular lobules could be seen; luminal epithelial cells that line of the lobules had strong staining for ACBD3, as do the myoepithelial basal layer of cells beneath (Figure 7b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel b",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel b",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "At 60× magnification, individual cells of the regular acini (Figure 7c) and irregular acini with invasive cells (Figure 7d) could be seen.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7e shows a core from an invasive ductal carcinoma, ACBD3 protein staining (brown) overall was low despite high coverage of haematoxylin nucleus staining (blue).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7f also shows an invasive ductal carcinoma and contained many more small ducts, and in this case, invasive cells in the ducts had higher staining of ACBD3 compared to the surrounding tissue.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel f",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7g shows a normal adjacent breast tissue core from a 41-year-old female with ducal ectasia.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel g",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7h shows a core of cancer adjacent tissue with benign adenosis (enlarged numerous lobules).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel h",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "ACBD3 Protein Expression in Malignant Breast Tissue and Metastatic Lymph Node Tissue\nThere was no statistical difference between ACBD3 protein expression between malignant breast tissue and metastatic breast cancer in lymph node (Figure 8a).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "ACBD3 protein levels were significantly higher in PR− breast cancers (mean = 3.296) compared to breast cancers with high expression of PR (PR 3+) (mean = 2.642) (* p = 0.022) (Figure 8b).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Although most normal-adjacent tissue cores detached during staining, three partial cores were scored and had a mean score of 2.70; whilst this small sample size could not reach any statistical conclusions, it was lower than the mean average for the breast cancer tissue cores overall (3.25), which is in keeping with the previous literature but contradictory to the results of Figure 8, where ACBD3 protein expression was higher in breast cancer cell lines than a normal-like breast cell control [22].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "ACBD3 Protein Expression Is Lower in Malignant Breast Tissue Compared to Cancer Adjacent and Normal Adjacent Breast Tissue\nContrary to previous reports [22], ACBD3 protein staining results for this array found ACBD3 protein staining to be statistically lower in malignant breast cancer tissue compared to adjacent tissue or normal adjacent tissue (Figure 8c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel c",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel c",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "ACBD3 Protein Expression in Malignant Breast Tissue of Multiple Subtype Receptor Status and Pathology\nArray BR1401 held no cases of breast cancer with PR 3+ receptor status, as such, the results from Figure 8b could not be corroborated in a larger sample size.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "HER2− breast cancer samples had significantly higher ACBD3 protein expression than HER2 1+ breast cancer samples (2.038, n = 49, versus 1.055, n = 4, respective mean averages, p = 0.0107) (Figure 8d).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Figure 7 represents typical ACBD3 staining of breast cancer tissue.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There were areas of higher staining at the ducts or lobules with surrounding tissue showing low or no staining for ACBD3 (Figure 7a).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel a",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "At 40× magnification, individual cells of both regular and irregular lobules could be seen; luminal epithelial cells that line of the lobules had strong staining for ACBD3, as do the myoepithelial basal layer of cells beneath (Figure 7b).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel b",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel b",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "At 60× magnification, individual cells of the regular acini (Figure 7c) and irregular acini with invasive cells (Figure 7d) could be seen.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel c",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel d",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7e shows a core from an invasive ductal carcinoma, ACBD3 protein staining (brown) overall was low despite high coverage of haematoxylin nucleus staining (blue).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel e",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7f also shows an invasive ductal carcinoma and contained many more small ducts, and in this case, invasive cells in the ducts had higher staining of ACBD3 compared to the surrounding tissue.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel f",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7g shows a normal adjacent breast tissue core from a 41-year-old female with ducal ectasia.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel g",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figure 7h shows a core of cancer adjacent tissue with benign adenosis (enlarged numerous lobules).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel h",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "ACBD3 Protein Expression in Malignant Breast Tissue and Metastatic Lymph Node Tissue\nThere was no statistical difference between ACBD3 protein expression between malignant breast tissue and metastatic breast cancer in lymph node (Figure 8a).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "ACBD3 protein levels were significantly higher in PR− breast cancers (mean = 3.296) compared to breast cancers with high expression of PR (PR 3+) (mean = 2.642) (* p = 0.022) (Figure 8b).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Although most normal-adjacent tissue cores detached during staining, three partial cores were scored and had a mean score of 2.70; whilst this small sample size could not reach any statistical conclusions, it was lower than the mean average for the breast cancer tissue cores overall (3.25), which is in keeping with the previous literature but contradictory to the results of Figure 8, where ACBD3 protein expression was higher in breast cancer cell lines than a normal-like breast cell control [22].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "There was no statistical difference between ACBD3 protein expression between malignant breast tissue and metastatic breast cancer in lymph node (Figure 8a).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "ACBD3 protein levels were significantly higher in PR− breast cancers (mean = 3.296) compared to breast cancers with high expression of PR (PR 3+) (mean = 2.642) (* p = 0.022) (Figure 8b).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Although most normal-adjacent tissue cores detached during staining, three partial cores were scored and had a mean score of 2.70; whilst this small sample size could not reach any statistical conclusions, it was lower than the mean average for the breast cancer tissue cores overall (3.25), which is in keeping with the previous literature but contradictory to the results of Figure 8, where ACBD3 protein expression was higher in breast cancer cell lines than a normal-like breast cell control [22].",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "ACBD3 Protein Expression Is Lower in Malignant Breast Tissue Compared to Cancer Adjacent and Normal Adjacent Breast Tissue\nContrary to previous reports [22], ACBD3 protein staining results for this array found ACBD3 protein staining to be statistically lower in malignant breast cancer tissue compared to adjacent tissue or normal adjacent tissue (Figure 8c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel c",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel c",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Contrary to previous reports [22], ACBD3 protein staining results for this array found ACBD3 protein staining to be statistically lower in malignant breast cancer tissue compared to adjacent tissue or normal adjacent tissue (Figure 8c).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel c",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel c",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "ACBD3 Protein Expression in Malignant Breast Tissue of Multiple Subtype Receptor Status and Pathology\nArray BR1401 held no cases of breast cancer with PR 3+ receptor status, as such, the results from Figure 8b could not be corroborated in a larger sample size.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "HER2− breast cancer samples had significantly higher ACBD3 protein expression than HER2 1+ breast cancer samples (2.038, n = 49, versus 1.055, n = 4, respective mean averages, p = 0.0107) (Figure 8d).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Array BR1401 held no cases of breast cancer with PR 3+ receptor status, as such, the results from Figure 8b could not be corroborated in a larger sample size.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "HER2− breast cancer samples had significantly higher ACBD3 protein expression than HER2 1+ breast cancer samples (2.038, n = 49, versus 1.055, n = 4, respective mean averages, p = 0.0107) (Figure 8d).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "High ACBD3 expression in ER+ patients was associated with poorer relapse-free survival (Figure 5c) supporting an interplay between ER signaling and ACBD3.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel c",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 8a looked broadly at local breast cancer tissue vs. breast cancer tissue that had invaded the lymph node; the data for both groups were skewed to the left (high stain scores) and had some resemblance of a bimodal distribution.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel a",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Rather than stratify the anatomic datasets, patients were instead divided by PR status (Figure 8b).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel b",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Array BC08032a (Figure 8c) contained fewer cores and was analyzed for ACBD3 expression across malignant, adjacent, and normal-adjacent tissue.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel c",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel c",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "HER2 0 cores on array BR1401 (Figure 8d) showed no evidence of non-normality (W = 0.9827, * p = 0.9997, n = 4).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel d",
        "figure_key": "figure_8"
      }
    ]
  }
]